CRSP250110P38000
- 0.03
- 0.000.00%
CRISPR Therapeutics Newsroom
CRISPR Therapeutics Analyst Ratings
BofA Securities Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating, Cuts Target Price to $85
JMP Securities Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating, Maintains Target Price $86
CRISPR Therapeutics Analyst Ratings
Clear Street Initiates CRISPR Therapeutics(CRSP.US) With Hold Rating, Announces Target Price $45
Piper Sandler Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating, Maintains Target Price $105
Chardan Capital Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating, Maintains Target Price $94
Evercore Maintains CRISPR Therapeutics(CRSP.US) With Hold Rating, Maintains Target Price $60
Crispr Therapeutics AG (CRSP) Gets a Hold From Evercore ISI
Analysts Are Bullish on Top Healthcare Stocks: Crispr Therapeutics AG (CRSP), Silence Therapeutics (SLN)
Chardan Capital Maintains Buy on CRISPR Therapeutics, Maintains $94 Price Target
CRISPR Therapeutics Analyst Ratings
William Blair Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating
Truist Financial Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating
Mizuho Securities Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating
Morgan Stanley Maintains CRISPR Therapeutics(CRSP.US) With Sell Rating, Maintains Target Price $45
A Quick Look at Today's Ratings for CRISPR Therapeutics(CRSP.US), With a Forecast Between $30 to $95
RBC Capital Reiterates Sector Perform on CRISPR Therapeutics, Maintains $53 Price Target
A Quick Look at Today's Ratings for CRISPR Therapeutics(CRSP.US), With a Forecast Between $30 to $94
Oppenheimer Sticks to Its Buy Rating for Crispr Therapeutics AG (CRSP)